Vericel Corporation $VCEL Shares Purchased by Mutual of America Capital Management LLC

Key Points

• Mutual of America Capital Management LLC increased its stake in Vericel Corporation by 6.0% during the second quarter, now owning 168,407 shares valued at approximately $7.17 million.
• Various analysts have recently revised their ratings and price targets for Vericel, with Canaccord Genuity lowering its target from $61 to $58 while Zacks upgraded it to a "strong-buy."
• Vericel reported earnings that beat estimates, showing a net margin of 2.85% and year-over-year revenue growth of 20.1%, with expectations for 0.14 earnings per share for the current fiscal year.

Mutual of America Capital Management LLC lifted its holdings in Vericel Corporation (NASDAQ:VCEL - Free Report) by 6.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 168,407 shares of the biotechnology company's stock after acquiring an additional 9,477 shares during the quarter. Mutual of America Capital Management LLC owned 0.33% of Vericel worth $7,166,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in VCEL. Ameritas Advisory Services LLC acquired a new stake in shares of Vericel in the second quarter worth $30,000. CWM LLC increased its stake in shares of Vericel by 101.3% in the second quarter. CWM LLC now owns 1,379 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 694 shares during the period. GAMMA Investing LLC increased its stake in shares of Vericel by 34.8% in the first quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company's stock worth $129,000 after acquiring an additional 748 shares during the period. US Bancorp DE increased its stake in shares of Vericel by 29.9% in the first quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company's stock worth $137,000 after acquiring an additional 706 shares during the period. Finally, Gagnon Securities LLC acquired a new stake in shares of Vericel in the first quarter worth $137,000.

Analysts Set New Price Targets

A number of research firms have recently weighed in on VCEL. Truist Financial cut their price objective on shares of Vericel from $46.00 to $41.00 and set a "buy" rating on the stock in a research note on Wednesday, October 15th. Zacks Research upgraded shares of Vericel from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, October 14th. Weiss Ratings restated a "sell (d+)" rating on shares of Vericel in a research report on Wednesday, October 8th. Canaccord Genuity Group dropped their price target on shares of Vericel from $61.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday, August 1st. Finally, BTIG Research lowered shares of Vericel from a "buy" rating to a "neutral" rating in a research report on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $58.40.

Vericel Stock Performance

VCEL stock opened at $36.02 on Tuesday. The firm has a market cap of $1.82 billion, a PE ratio of 300.19 and a beta of 1.39. The firm's fifty day moving average is $33.71 and its 200 day moving average is $38.17. Vericel Corporation has a one year low of $29.24 and a one year high of $63.00.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The business had revenue of $63.24 million for the quarter, compared to analyst estimates of $64.61 million. During the same quarter last year, the business earned ($0.10) earnings per share. The company's revenue for the quarter was up 20.1% compared to the same quarter last year. Research analysts predict that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corporation (NASDAQ:VCEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.